Related Experiment Video

Updated: Jun 5, 2025

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.2K

Sirtuins as Key Regulators in Pancreatic Cancer: Insights into Signaling Mechanisms and Therapeutic Implications

Surbhi Chouhan1,2, Anil Kumar3, Naoshad Muhammad4

  • 1Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75235, USA.

Cancers
|December 17, 2024
PubMed

Insights

Sirtuins, NAD+-dependent enzymes, play key roles in pancreatic cancer. Modulating their activity offers new therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC).

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with poor treatment outcomes.
  • Sirtuins, NAD+-dependent deacetylases, are increasingly recognized as critical regulators in PDAC.
  • Dysregulated sirtuin activity contributes to tumor progression, chemoresistance, and metastasis.

Purpose of the Study:

  • To comprehensively review the multifaceted roles of sirtuins in pancreatic cancer.
  • To elucidate how sirtuins impact tumorigenesis, suppression, and metabolic reprogramming in PDAC.
  • To highlight the therapeutic potential of targeting sirtuin activity for improved patient outcomes.

Main Methods:

  • Literature review of sirtuin involvement in PDAC.
  • Analysis of sirtuin functions in apoptosis, metabolism, and epigenetic regulation.
  • Exploration of sirtuin modulators as potential therapeutic agents.

Main Results:

  • SIRT1 promotes chemoresistance via hypoxia and glycolysis.
  • SIRT2 inhibits proliferation, while SIRT3 and SIRT4 exhibit tumor-suppressive roles.
  • SIRT5, SIRT6, and SIRT7 are implicated in metabolic dependencies, angiogenesis, and metastasis.

Conclusions:

  • Sirtuins are crucial regulators in pancreatic cancer, influencing diverse oncogenic processes.
  • Targeting specific sirtuins presents a promising therapeutic avenue for PDAC.
  • Further research into sirtuin modulation is essential for developing effective pancreatic cancer treatments.
Keywords:
SIRTcancer signaling pathwaysdeacetylasepancreatic cancerpancreatic ductal adenocarcinoma (PDAC)sirtuinstherapeutic interventions

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

719
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K